Import and exportPharmaceuticalsQuasi-drugsFood productsManufacture and sale of medical devices, etc.Development and sale of dysmenorrhea treatmentsDevelopment and sale of oral contraceptivesResearch and developmentDrug discovery research recruitmentPipeline and intellectual property strategyProductionMedical information provision activitiesReliability assurance
Launched hyperlipidemia treatment drug "Lipdil Tablets"
Completed Iwaki Factory and Quality Control Building
Established a subsidiary, Asuka Animal Health Co., Ltd.
Launched treatment drug for endometriosis, uterine fibroids, and prostate cancer, 'Lupron Acetate Injection Kit Asuka'.
Launched antihypertensive drug 'Candesartan Tablets Asuka'.
Asuka Pharmaceutical celebrates its 10th anniversary.
Transferred sales and manufacturing approval of antithyroid drugs 'Mercazole Tablets', 'Mercazole Injections', and 'Propylthiouracil Tablets' from Chugai Pharmaceutical Co., Ltd.
Completion of Iwaki Factory and Fourth Formulation Building.
Launched infertility treatment drug 'Luteum Vaginal Suppositories'.
Launched hepatic encephalopathy treatment drug 'Refximia Tablets'.
Invested jointly with Omnicare Drugs India Private Limited in NeoASKA Pharma Private Limited in India.
Launched dysmenorrhea treatment drug 'Frewell Combination Tablets LD/ULD Asuka'.
Launched uterine fibroid treatment drug 'Lermina Tablets' (additional indication for endometriosis in December 2021).
Transferred sales and manufacturing approval of uterine contraction suppressant 'Magcent Injections', 'Magcent Syringe Injections', and eclampsia suppression and treatment drug 'Magnesol for Injection' from Toa Pharmaceutical Industry Co., Ltd.
Relocated Kawasaki Research Institute to Shonan Health Innovation Park: Started as 'Shonan Research Institute'.
Established Asuka Pharmaceutical Holdings Co., Ltd.
Established an international office in London, UK.
Yamaguchi Sōdai appointed as President.
Launched dysmenorrhea treatment drug 'Droethy Combination Tablets Asuka'.
Launch of oral contraceptive 'Sundinda Tablets 28'
§07
News
63 ARTICLES
Results Published for PMS/PMDD Therapeutic App Trial
ASKA Pharmaceutical announced that results of a specified clinical trial of a therapeutic app for premenstrual syndrome and premenstrual dysphoric disorder have been published on Japan’s jRCT registry. The trial was conducted in collaboration with SUSMED and Professor Mariko Ogawa of Fukushima Medical University.
Clinical Study Results of an App for Treating Premenstrual Symptoms Published
Asuka Pharmaceutical and Sasemed, in collaboration with Professor Mariko Ogawa of Fukushima Prefectural Medical University, conducted a specific clinical study on a therapeutic app targeting patients with premenstrual syndrome or premenstrual dysphoric disorder. The study results were published on the Clinical Research Information Service (jRCT). This does not affect Asuka Pharmaceutical's fiscal year ending March 2027 performance.
Experience-Based Menstrual Seminar "Menstrual Lab®" for Sony Network Communications Employees
Asuka Pharmaceutical Co., Ltd. and Asai Co., Ltd. conducted a seminar for Sony Network Communications employees, where participants learned about menstrual health issues such as menstruation and PMS through a training video supervised by obstetricians and gynecologists and an experiential session using artificial menstrual blood. Participants reported re-evaluating their own symptoms and gaining new insights from others' experiences.
Training Service for Managers Supporting Fertility Treatment Launched
Asuka Pharmaceutical Co., Ltd. and Rupan Consulting launched the training service "Work Health Palette (Fertility Treatment Edition)" on November 10, 2026, focusing on supporting the balance between fertility treatment and work. The service primarily targets managers, providing a structured program to learn about the medical basics of fertility treatment, workplace responses, and career support.
Workstyle Reform for Women! Menstrual Comfort Project Media Seminar
Aska Pharmaceutical Medical Co., Ltd., in cooperation with Fuji Pharma Co., Ltd., will hold a media seminar on December 4, 2026, as part of the “Workstyle Reform for Women! Menstrual Comfort Project,” organized by the Nikkei BP Research Institute. The seminar will be held in a hybrid format, with both in-person attendance and a live stream, and will explain to members of the press the impact of menstrual symptoms on work and the importance of treatment and creating supportive environments.
ASKA Pharmaceutical selected for AMED’s GRiT program
ASKA Pharmaceutical has been selected for the 2026 fiscal year Grant Program for Research and Development on Rare and Intractable Diseases (GRiT), sponsored by AMED (Japan Agency for Medical Research and Development). This selection marks an important step toward advancing the company’s investigational drug AKP-021 into a Phase II clinical trial in patients with IC/BPS.
AKP-021 Development Selected for AMED GRiT Project
The research and development challenge "Verification of efficacy and safety assessment for IC/BPS patients using AKP-021" by Asuka Pharmaceutical has been selected for AMED's 2026 fiscal year Global Research and Development Support Project for Rare and Intractable Diseases (GRiT). We will advance development toward a Phase II clinical trial targeting IC/BPS patients. In this public solicitation, 25 projects were submitted and 8 were selected.
ASKA Pharmaceutical enters agreement for Wellnara® manufacturing and marketing rights
TOKYO, November 4, 2026 – ASKA Pharmaceutical Holdings Co., Ltd. announced that its subsidiary, ASKA Pharmaceutical Co., Ltd., has entered into an agreement to transfer the manufacturing and marketing authorization and related marketing rights in Japan for Wellnara® Combination Tablets, an oral estrogen therapy. The agreement will enable the subsidiary to manufacture and market the product within Japan.
ASKA Pharma Launches Drospirenone Trial
ASKA Pharmaceutical Holdings announced the start of a Phase III clinical trial in Japan for its drospirenone formulation LPRI-CF113, targeting patients with dysmenorrhea. The trial, named PROFILE-D, will compare the new drug against existing progestin therapies in a randomized head‑to‑head design. The study aims to evaluate efficacy and safety in the obstetrics and gynecology field.
ASKA Pharma Licenses MHB018A for TED
ASKA Pharmaceutical Holdings Co., Ltd. announced that it has entered into a license agreement for MHB018A, a therapeutic candidate for thyroid eye disease (TED). The agreement positions ASKA Pharma to advance the development and potential commercialization of MHB018A for patients with TED.
§08
Public records
GOV
National Tax Agency basic information5020001066661
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
株式会社あすか製薬メディカル
Trade name (kana)
アスカセイヤクメディカル
Name in English
Corporation type
301
Address
〒251-0012 神奈川県藤沢市村岡東2丁目26-1湘南ヘルスイノベーションパーク内
Postal code
2510012
Prefecture code
14
City code
205
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2020-04-07
Change date
2020-04-02
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2779244
METI gBizINFO5020001066661
Source: gBizINFO (Ministry of Economy, Trade and Industry)